Compare ZDGE & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDGE | PSTV |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 37.2M |
| IPO Year | 2016 | 2016 |
| Metric | ZDGE | PSTV |
|---|---|---|
| Price | $3.12 | $5.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $55.00 |
| AVG Volume (30 Days) | 63.6K | ★ 131.2K |
| Earning Date | 06-11-2026 | 05-29-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | 73.85 | ★ 87.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,398,000.00 | $5,213,000.00 |
| Revenue This Year | $3.27 | $13.20 |
| Revenue Next Year | $5.78 | $261.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.21 | $0.13 |
| 52 Week High | $4.70 | $8.00 |
| Indicator | ZDGE | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 49.26 |
| Support Level | $2.87 | $5.28 |
| Resistance Level | $3.43 | $6.65 |
| Average True Range (ATR) | 0.16 | 0.54 |
| MACD | 0.03 | -0.16 |
| Stochastic Oscillator | 79.17 | 23.94 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).